GRADE 1 FOLLICULAR LYMPHOMA

This early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose and see how well the drugs work togethe…

This study is for people with a slow-growing type of blood cancer called follicular lymphoma that has come back or is not responding to treatment. It compares the drug obinutuzumab alone versus obinutuzumab combined with other drugs (umbralisib, lenalidomide, or chemotherapy) to …

This study tests a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) in 40 people with untreated stage II-IV follicular lymphoma. The goal is to see if the combination works better than each drug alone at shrinking tumors. Participants receive all three drugs a…

This study tests whether combining two drugs—obinutuzumab and ibrutinib—can shrink or eliminate slow-growing non-Hodgkin's lymphoma in people who haven't been treated before. About 30 adults with various stages of the disease will receive the drugs as their first therapy. The goa…

This early-phase study tests whether adding the drug acalabrutinib to CAR T-cell therapy (axicabtagene ciloleucel) is safe and works better for people with certain B-cell lymphomas. About 23 adults whose cancer has not responded to prior treatments will receive the combination. T…